The Ebola virus disease, which spread in four West African countries, brought to light the feeble health governance system not only in these countries but also at the global level. Weak health infrastructure, resource crunch, non-viability of preventive and curative medication, and distrust of foreign interventions among people not only aggravated the crisis but also led to a schizophrenic portrayal of the disease across the world. A lack of any preventive medication for Ebola--despite a history of recurrence over the last four decades--is a big question confronting health research communities, pharmaceutical companies and global health governing agencies. The recent outbreak of Ebola and a global security threat perception associated with the disease have given rise to many debates, one of them being the debate on medical ethics in a public health emergency. All the ethical issues related with the unavailability of medication, launch of untested medicine in affected areas and also the delay in decision-making and response are the core arguments which this article tries to analyse.
